Summary
This international multi-centre cohort study investigated the prevalence and clinical significance of FGFR3 mutations and expression in a large bladder cancer population treated by radical cystectomy. As suggested by the title, the findings provide insights into patient stratification for anti-FGFR3 targeted therapies, though specific efficacy outcomes require consultation of the full manuscript. The work contributes to understanding molecular heterogeneity in bladder cancer and potential therapeutic implications.
UK applicability
Findings are directly applicable to UK urology and oncology practice, given the international cohort composition and the relevance of radical cystectomy as standard of care in the United Kingdom. Results may inform molecular testing and treatment selection pathways in UK cancer services.
Key measures
FGFR3 mutation status, FGFR3 protein expression levels, clinicopathological outcomes in radical cystectomy patients
Outcomes reported
The study examined FGFR3 mutation status and protein expression levels in a large cohort of bladder cancer patients who underwent radical cystectomy, with implications for targeted anti-FGFR3 therapeutic strategies.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.